New drugs, is a good heart "…
FDA approved for the prevention of stroke, dabigatran embolism in patients AF 
The good news for the German Pharma, Boehringer Ingelheim.The US FDA has approved its recently antithrombin dabigatran, marketed as Pradaxa on the American market.Pradaxa is indicated for the prevention of systemic Embolism and stroke in patients with atrial fibrillation. approval is a guide, on the risk of serious bleeding as a side effect of other side effects include gastrointestinal symptoms, dyspepsia, stomach pain, nausea, heartburn, and flatulence.
Existing drugs, which may be bad for the heart ...
Abbott Laboratories is obliged to take back their obesity drug Meridia
Abbott Laboratories is voluntarily withdrawing its obesity drug Meridia (sibutramine) on the American market due to safety issues. "this is the American FDA, following a review of data from clinical trial data that indicated an increased risk for heart attack and stroke on the basis of the application.
According to Dr. John Jenkins, Director of the Office of new drugs in the FDA's Center for Drug Evaluation and Research (CDER):
"The continued availability of Meridia is not a reason when comparing the loss in mass is very modest, which people achieve this remedy for their risk of heart attack or stroke, we recommend that you stop the prescribing Doctors. Meridia to their patients and patients stop taking this drug.Patients should ask their health care provider about weight loss and weight loss maintenance alternative programs. "
Invirase (saquinavir): change the label – risk unusual heart Rhythm
Security alerts on the antivirus drug Invirase (saquinavir): risks for arrhythmia (abnormal heart rhythm) due to changes in the electrical activity of the heart with Norvir (ritonavir), other antivirus medication. Both medicines are used to treat HIV infection has been added. notice of the label Invirase.
FDA: contains the warnings for the class of prostate drugs
Safety issues are also faced with agonists gonadotropin-releasing hormone (GnRH), a class of drugs, is used primarily to treat men with a prostate. Warnings are added to the labels on the potential risk of heart disease and diabetes for those taking these drugs. GnRH agonists are placed on the market in the United States under the following brands: Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur and Zoladex but they are also available in generic form.
Loading ...
View the original article here
